Intranasal Insulin and Its Effect on Postprandial Glucose Metabolism in Comparison to Subcutaneous Insulin.

Trial Profile

Intranasal Insulin and Its Effect on Postprandial Glucose Metabolism in Comparison to Subcutaneous Insulin.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Insulin (Primary) ; Insulin aspart
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors CPEX Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2010 Planned end date changed from 1 Jan 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
    • 12 Jul 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 12 May 2009 Planned initiation date (Jul 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top